Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026

Rhea-AI Summary

Jupiter Neurosciences (NASDAQ: JUNS) will present at the BIO Investment and Growth Summit 2026 on March 2, 2026 at 2:30 PM ET in Miami Beach. Management will discuss an FDA-cleared IND and the company’s ongoing Phase IIa Parkinson’s program and commercial progress with Nugevia.

Jupiter cites IND clearance in November 2025, preclinical JOTROL bioavailability improvements, repeat purchase rates ~25%, and ~3% return rates as early commercial validation.

News Market Reaction – JUNS

-4.38%

3 alerts

-4.38% Session close to close

-8.8% Trough Tracked

$17.21M Market Cap

0.6x Rel. Volume

In the Mar 2 session, JUNS declined 4.38%, reflecting a moderate negative market reaction. Argus tracked a trough of -8.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Jupiter’s participation at a major BIO summit and continued emphasis on...

Analysis

This announcement highlights Jupiter’s participation at a major BIO summit and continued emphasis on its FDA-cleared Phase IIa Parkinson’s program and Nugevia™ commercialization. Key data points include a reported 9-fold JOTROL™ bioavailability improvement, repeat purchases near 25%, and returns around 3%. In context with recent investor events and capital arrangements, investors may focus on clinical enrollment progress, sustained ecommerce metrics, and any updates related to Nasdaq listing compliance as noted in prior filings.

Key Figures

Phase IIa program: Phase IIa Bioavailability improvement: 9-fold Conference dates: March 2–3, 2026 +3 more

6 metrics

Phase IIa program Phase IIa Parkinson’s disease trial cleared by FDA IND in November 2025

Bioavailability improvement 9-fold JOTROL bioavailability vs standard resveratrol formulations in preclinical data

Conference dates March 2–3, 2026 BIO Investment and Growth Summit in Miami Beach, Florida

Presentation time 2:30 PM Scheduled corporate presentation on March 2, 2026

Repeat purchase rate 25% Publicly disclosed ecommerce repeat purchases for Nugevia

Product return rate 3% Publicly disclosed ecommerce product return rate for Nugevia

Historical Context

5 past events · Latest: Feb 25 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 25	Investor presentation	Neutral	+0.9%	Private Mar-a-Lago investor dinner highlighting Phase IIa and Nugevia progress.
Feb 23	Financing amendment	Neutral	+0.0%	Yorkville installment deferral to align capital timing with execution.
Jan 28	Commercial strategy	Neutral	-23.5%	Nugevia GLP-1 market expansion and longevity positioning update.
Jan 27	Conference appearance	Neutral	-0.0%	DealFlow Discovery Conference presentation and investor meetings.
Dec 23	Investor webinar	Neutral	-2.7%	Announcement of January 6 webinar on JOTROL and Phase IIa plan.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent investor-relations and commercial updates have produced mostly small price moves, with one notably sharp selloff on a Nugevia-focused announcement.

Recent Company History

Over the last few months, Jupiter Neurosciences has emphasized investor outreach and its dual-path strategy. Events include an investor webinar on January 6, 2026, a conference appearance on January 28–29, 2026, and a Mar-a-Lago investor dinner on February 25, 2026. Financing alignment with Yorkville, including deferring installments to April 1, 2026, supports clinical and commercial execution. A Nugevia™ GLP‑1 positioning update on January 28, 2026 coincided with a -23.53% move, contrasting with smaller reactions to other news.

Key Terms

phase iia, neuroinflammation, investigational new drug (ind), bioavailability, +1 more

5 terms

phase iia medical

"Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation"

Phase IIa is an early mid-stage clinical study that tests whether a new drug or treatment shows the intended biological effect in patients and helps identify the best dose. Think of it as a focused test-drive to see if a medicine does what it’s supposed to and what dose is tolerable before larger trials. Investors watch Phase IIa results because positive findings reduce technical risk and can materially increase the program’s value, while negative results raise the likelihood of costly delays or failure.

neuroinflammation medical

"Phase IIa Parkinson’s Program Targeting Neuroinflammation Dual-Path Strategy"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

investigational new drug (ind) regulatory

"FDA granted the Company’s Investigational New Drug (IND) application authorizing initiation"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

bioavailability medical

"nine-fold improvement in JOTROL™ bioavailability compared to standard resveratrol"

Bioavailability is the measure of how much and how quickly a substance, such as a medication or nutrient, enters the bloodstream and becomes available for use by the body. For investors, it matters because it influences how effectively a product works and how quickly results are seen, which can impact a company's success and the potential value of related investments. Think of it like how much of a medicine actually reaches your bloodstream after taking it—that determines how well it can do its job.

proof-of-concept medical

"documented translational proof-of-concept in Parkinson’s disease models"

A proof-of-concept is a demonstration that shows a new idea or method can work as intended, serving as a small-scale test before full development. For investors, it signals that a concept has been successfully tested in principle, reducing uncertainty about whether it can be practically implemented. This helps determine if further investment or effort is justified to develop the idea further.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting Neuroinflammation

Dual-Path Strategy Combines Clinical Development with Revenue-Generating Nugevia^™

JUPITER, FL, March 02, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that management will participate in the BIO Investment and Growth Summit 2026, hosted by the Biotechnology Innovation Organization (BIO), taking place March 2 to 3, 2026 in Miami Beach, Florida. The Company’s corporate presentation is scheduled for March 2, 2026, at 2:30 PM.

At BIO, Jupiter will discuss its FDA-cleared Phase IIa clinical program in Parkinson’s disease. In November 2025, the U.S. Food and Drug Administration granted the Company’s Investigational New Drug (IND) application authorizing initiation of the trial. The IND clearance followed previously reported preclinical data demonstrating a nine-fold improvement in JOTROL^™ bioavailability compared to standard resveratrol formulations, and documented translational proof-of-concept in Parkinson’s disease models, supporting the scientific rationale for clinical advancement.

“We approach development with discipline and a clear execution plan,” said Christer Rosén, Chairman and Chief Executive Officer. “With our Phase IIa program underway and defined milestones in front of us, we look forward to engaging with investors and potential partners at BIO. At the same time, we continue building revenue and commercial cash flow through Nugevia.”

In addition to advancing its clinical pipeline, Jupiter is generating revenue through Nugevia^™, a consumer product built on its patented JOTROL^™ technology platform designed to enhance resveratrol bioavailability. Publicly disclosed ecommerce performance reflects repeat purchase activity of approximately 25 percent and product return rates of approximately 3 percent. Management believes these metrics demonstrate early commercial validation and support a capital-efficient operating model that differentiates Jupiter from biotechnology peers that rely solely on external financing.

“We remain confident in our plan and the actions underway regarding recent Nasdaq communications,” Rosén added. “In our view, there is no better remedy than disciplined execution, delivering clinical milestones while continuing to build revenue and commercial cash flow through Nugevia.”

Management will be available for scheduled one-on-one meetings throughout the conference.

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neuroinflammation and central nervous system disorders. The Company’s lead clinical program is advancing through a Phase IIa trial in Parkinson’s disease. Jupiter is also commercializing Nugevia^™, a consumer product built on its patented JOTROL^™ technology platform designed to enhance resveratrol bioavailability. Jupiter’s dual-path strategy combines clinical development with commercial revenue generation.

For more information, visit www.jupiterneurosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements. These statements include, but are not limited to, statements regarding clinical development, commercialization plans, revenue growth, capital planning and future operating performance. Factors that could cause actual results to differ materially include clinical trial outcomes, regulatory developments, market acceptance of Nugevia, capital market conditions, Nasdaq listing requirements and other risks described in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements except as required by law.

Investor Contact
Jupiter Neurosciences, Inc.
1001 North US Highway 1, Suite 504
Jupiter, FL 33477
Email: ir@jupiterneurosciences.com

FAQ

When will Jupiter Neurosciences (JUNS) present at the BIO Investment and Growth Summit 2026?

Jupiter Neurosciences will present on March 2, 2026 at 2:30 PM ET. According to Jupiter Neurosciences, management will also hold scheduled one-on-one meetings during the March 2–3, 2026 conference in Miami Beach.

What is the status of JUNS's Phase IIa Parkinson’s program after the IND clearance?

The Phase IIa Parkinson’s program is authorized to proceed following IND clearance in November 2025. According to Jupiter Neurosciences, the clearance follows preclinical data showing improved JOTROL bioavailability and translational proof-of-concept supporting clinical advancement.

How is Jupiter Neurosciences (JUNS) generating revenue with Nugevia while running clinical trials?

Jupiter is generating revenue through sales of Nugevia, a consumer product using JOTROL technology. According to Jupiter Neurosciences, ecommerce shows ~25% repeat purchase activity and ~3% product return rates as early commercial validation.

What preclinical evidence supports JUNS’s clinical program for Parkinson’s disease?

Preclinical data reported a nine-fold improvement in JOTROL bioavailability versus standard resveratrol formulations. According to Jupiter Neurosciences, that improvement plus translational Parkinson’s models underpin the scientific rationale for the Phase IIa trial.

How did Jupiter Neurosciences (JUNS) address recent Nasdaq communications at BIO 2026?

Management emphasized disciplined execution and milestone delivery as its remedy following recent Nasdaq communications. According to Jupiter Neurosciences, the company aims to advance clinical milestones while continuing to build Nugevia-driven commercial cash flow.